Every so often, a study comes along that changes how an industry thinks.
I believe the recently published ATLAS meta-analysis is one of those studies. I had the pleasure of hearing the impact of this when the data was presented at the recent European Stroke Organisation Conference in Maastricht, The Netherlands.
ATLAS brings together data from six major randomised trials involving almost 1,900 patients with large-core ischaemic stroke. Led by Amrou Sarraj and an international group of stroke researchers, the study provides the strongest evidence to date that many patients whose large core infarcts were previously considered too severe for thrombectomy can still benefit from treatment.
That is a significant finding.
For years, the stroke community has wrestled with the question of where the limits of thrombectomy really are. Who do we select? Which is the sweet spot in terms of the treatment window? ATLAS moves those boundaries meaningfully and gives clinicians greater confidence to treat patients who may previously have been excluded.
The implications extend well beyond clinical practice and into industry.
If more patients are eligible for thrombectomy, more patients need to be identified quickly, transferred efficiently and treated in specialist centres. The challenge increasingly becomes one of access, workflow and capacity.
For those working at the front line in stroke care, ATLAS also highlights something else.
While thrombectomy continues to improve outcomes, too many patients still experience significant disability following stroke. The next chapter of innovation is therefore unlikely to focus on whether patients should be treated. Instead, it will focus on how we improve outcomes for the growing number of patients who do receive thrombectomy.
That means advancing every stage of the patient journey, from faster identification and transfer through to procedure planning, treatment execution and post-stroke recovery. It means expanding workforce capacity, equipping clinicians with better tools and training, and using data more effectively to understand the factors that influence outcomes. As thrombectomy becomes available to more patients, the industry’s challenge shifts from proving the value of treatment to maximising the benefit each patient receives from it.
Most importantly, it means more patients may have the opportunity to receive life-changing treatment via thrombectomy. That is progress worth celebrating.
Michael Macilquham
CEO of Nicolab
Find the ATLAS study here
